Investor Presentation Q1 2023

71 Investor presentation First three months of 2023 Building upon a 40-year legacy to capture the Rare disease strategic opportunity A strategy anchored in Rare blood and endocrine disorders Three strategic horizons towards 2030 Hemato-renal Haemoglobinopathies Haemolytic anaemia Iron disorders Haemophilia HV Lysosomal storage disorders Rare pituitary & adrenal disorders Bone/calcium imbalances Growth disorders Growth hormone disorders Novo NordiskⓇ Short-term Maximise current portfolio Medium-term Succeed with next- generation launches Long-term Expand from core New disease areas via accelerated internal and external innovation RBD RED Rare blood disorders Rare endocrine disorders esperoct norditropin® turoctocog alfa pegol refixia® nonacog beta pegol (somatropin) injection NovoSevenⓇRT Coagulation Factor Vila (Recombinant) SOGROYA somapacitan Concizumab & Mim8 Nedosiran

View entire presentation